ExCellThera annonce les résultats positifs des études de phase 2 de la thérapie cellulaire UM171 chez des patients atteints de leucémies et de myélodysplasies à haut risque lors du congrès annuel 2023 de l'American Society of Hematology (ASH)
12 déc. 2023 07h00 HE
|
ExCellThera
- Données présentées lors d'une séance orale à l'ASH 2023, s'appuyant sur des données solides antérieures issues d'une étude de phase 1/2 et d'études comparatives de registres. - La thérapie...
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
12 déc. 2023 05h15 HE
|
ADC Therapeutics SA
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC...
Be The Match Announces Winners of 2023 NMDP/Be The Match Awards
27 nov. 2023 10h21 HE
|
Be The Match
NMDP/Be The Match® announces the recipients of its annual NMDP/Be The Match Awards at The ONE Forum 2023.
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
09 nov. 2023 16h01 HE
|
Vor Biopharma
Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor...
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
07 nov. 2023 16h05 HE
|
Vor Biopharma
Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023...
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
07 nov. 2023 07h30 HE
|
Adaptive Biotechnologies
Data generated by Adaptive’s next-generation sequencing-based MRD assay will support the development and commercialization of investigational medicines for hematologic malignancies SEATTLE, Nov. 07,...
ExCellThera announces new UM171 data to be presented at ASH 2023
03 nov. 2023 08h15 HE
|
ExCellThera
ExCellThera announced today several UM171 presentations at ASH2023, including new data from Phase 2 studies in high-risk blood cancer patients
Vor Bio to Participate in Upcoming Investor Conferences
03 nov. 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
The International Myeloma Foundation is Creating an Award-Winning Tool for Nurses to Improve Myeloma Patient Outcomes in Underserved Communities
02 nov. 2023 13h15 HE
|
International Myeloma Foundation
The International Myeloma Foundation wins the 2023 Sanofi HealthEquity Accelerator Award for their program which empowers nurses and tackles disparities.
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
02 nov. 2023 09h01 HE
|
Vor Biopharma
Three oral and two poster presentations accepted by ASHCompany to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and...